Roche and Cambridge Quantum Computing Use Algorithms for Early Alzheimer's Drug Research

BioPharm International Editors

The companies intend to design and implement algorithms for the early stages of research for drug discovery and development of drug candidates to treat Alzheimer’s disease.

In a recently formed collaboration with Roche, Cambridge Quantum Computing (CQC) will design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early stage drug discovery and development. The multi-year collaboration will combine the industry expertise of both companies to significantly advance the application of quantum computing to pharmaceutical-relevant problems, with the aim of accelerating the industry closer towards quantum advantage.

The collaboration, formed in late January 2021, will employ CQC’s quantum chemistry platform EUMEN, to augment Roche’s Alzheimer’s Disease research efforts and will be considered a substantive research effort in the field of quantum computing. The collaboration will strive to enable the development of next-generation, quantum-inspired therapeutics.

“For many years quantum computing has held out great promise for discovering new therapeutics that aid humanity in fighting some of the most devastating and damaging diseases. We are pleased that due to the careful and pioneering efforts of our research teams, some of this promise is starting to come to fruition. We are excited to collaborate with Roche and their quantum computing taskforce. It is a true privilege to collaborate in pursuit of quantum advantage,” said Ilyas Khan, CEO of CQC, in a company press release.

Source: Cambridge Quantum Computing